Panacos Pharmaceuticals (PANC)., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat Human Immunodeficiency Virus (HIV) and other human viral diseases. Its lead product candidate, bevirimat, under Phase 2 clinical trials, is a class of drug candidates that works by a novel mechanism of action called maturation inhibition. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. It also has research and development programs designed to generate second and third-generation maturation inhibition products; and a research and development program focused on an early step in the HIV virus life cycle, fusion of the HIV virus to human cells. Stock is trading toward year lows. We see limited downside risk from current lows.
$2.89 (09/05/07)
Agree
Disagree
